• Raúl Carrillo-Esper, Santos Rivera-Buendía, Jorge Raúl Carrillo-Córdova, and Luis Daniel Carrillo-Córdova.
• Unidad de Terapia Intensiva, Fundación Clínica Médica Sur, México D.F., México. seconcapcma@mail.medinet.net.mx
• Gac Med Mex. 2007 Nov 1;143(6):499-503.

AbstractSepsis continues to be a major cause of morbidity and mortality. Evidence is emerging from observational studies and basic science research that statins might be associated with reduced mortality in sepsis. Statins have diverse immunomodulatory and antiinflammatory properties independent of their lipid-lowering ability. The protective association between statins and sepsis persisted in high-risk subgroups including patients with diabetes mellitus, those with malignancy, and those receiving steroids. This review discusses the basis of these observations and the current place of statin therapy in patients with sepsis. This is a rapidly growing field of fascinating experimental biology. It suggests an urgent need to investigate the pharmacology of these drugs and reappraise their therapeutic indications in critically ill patients. If this finding is supported by prospective controlled trials, statins may play an important role in sepsis related mortality. By the other hand statins are significantly cheaper than other therapies that have been shown to improve outcome in sepsis, and the demonstration of mortality benefit would have enormous cost-benefit implication.

6 keywords...

hide…